Oncology Medical News about Migraine Disorders Trastuzumab

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Nanotech Effort with Glioblastoma - Impressive or Impractical?

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Throbbing Pain in the Head: Trastuzumab-induced Migraine
Anticancer Research, 11/06/09

Van Rooij F et al. – Trastuzumab, an epidermal growth factor receptor inhibitor, is used in the treatment of both early–stage and metastatic breast cancer. In general it is well tolerated, with a flu–like syndrome occurring frequently a few hours after administration, including symptoms such as fever, sweating, skin rash, nausea and headache. A migraineous headache however has never been described as an adverse event. Here the authors present a patient in whom a strong relationship between trastuzumab infusion and a migraineous headache syndrome was present, without evidence of metastatic disease. Treatment with corticosteroids for the infusion–related complaints resulted in significant pain relief.

<< Previous
Tumour formation by single fibroblast growth factor receptor...

Next >>
Epidermal growth factor receptor expression escapes androgen...